Health care use and costs in Medicare Advantage patients using GLP-1 receptor agonists compared to SGLT-2 inhibitors
Updated
Abstract
The matched cohort included 22,167 individuals initiating treatment with either GLP-1 receptor agonists or SGLT2 inhibitors.
- No significant differences were observed in all-cause or diabetes-related inpatient stays or emergency department visits between users of GLP-1 RA and SGLT2i.
- Overall medical costs were 3.1% higher for GLP-1 RA users compared to SGLT2i users.
- In the obesity subgroup, GLP-1 RA users had 2.9% lower medical costs than those on SGLT2i.
- Pharmacy costs for patients on GLP-1 RA were 6% to 9% higher than those on SGLT2i.
- Total health care costs were 4% to 6% higher for GLP-1 RA users compared to SGLT2i users.
Simplified
Funding
Competing interests
Humana Healthcare Research, Inc., funded the research and manuscript development. No external funds were used in the creation of this work. Dr Poonawalla, Ms Dixon, and Mr Bowe are salaried employees of Humana Healthcare Research, Inc. Drs Abdal, Hayes, John, and Diaz are salaried employees of Humana Inc., which offers Medicare Advantage health plans. Drs Poonawalla, Abdal, Hayes, John, and Diaz own Humana stock earned as part of their employment.
PubMed